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Background: The aim of this study is to evaluate whether the associations between clinicopathologic factors of
papillary thyroid microcarcinoma (PTMC), especially tumor size, and subclinical central lymph node metastasis (LNM)
are dependent on patient age.
Methods: The medical records of 428 patients who underwent thyroid surgery for PTC measuring ≤1 cm were
reviewed. All patients were clinically lymph node negative and underwent thyroidectomy with unilateral or bilateral
central lymph node dissection. Univariate and multivariate analyses were performed to identify clinicopathologic
factors associated with central LNM.
Results: Central LNM was identified in 96 of 428 (22.4%) patients. Mean tumor size was significantly greater in
patients with than without central LNM (0.74 ± 0.22 cm vs. 0.64 ± 0.23 cm, P = 0.001). Tumor size > 0.5 cm was
significantly predictive of central LNM. Subgroup analysis according to age groups showed that tumor size was an
independent predictor of subclinical central LNM only in patients aged ≥45 years.
Conclusions: Factors predictive of central LNM in patients with PTMC differed by age. PTMC size was an
independent predictor of subclinical central LNM only in patients aged ≥45 years.
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The incidence of thyroid cancer, especially of small
tumors measuring ≤1 cm, has been rapidly increasing,
due primarily to advances in ultrasonography and fine
needle aspiration cytology of the thyroid [1,2]. Although
most papillary thyroid microcarcinomas (PTMCs) have
an indolent course and excellent prognosis, the long-
term recurrence rate of PTMC has been reported to be
as high as 12% [3-7], with lymph node metastasis (LNM)
being one of the most important factors associated with
local recurrence and distant metastasis [6,8,9].
The standard care for patients with thyroid cancer and
involved lymph nodes is total thyroidectomy plus thera-
peutic cervical lymph node dissection. However, it has
not yet been determined whether routine central lymph* Correspondence: drjej@gnu.ac.kr
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unless otherwise stated.node dissection should be performed in patients with
PTMC but without evident LNM. To date, no ran-
domized controlled trials have found that prophylactic
central lymph node dissection has prognostic value
[10,11]. Although preoperative ultrasonography is com-
monly recommended in staging of diseases of the thyroid
and cervical lymph nodes, this method has limitations in
diagnosing central LNM. Its sensitivity and specificity are
lower within the central compartment (27.3% to 55% and
69% to 90.3%, respectively) than within the lateral com-
partment (65% to 90.3% and 82% to 94.8%) [12-15]. Thus,
several studies have investigated the preoperative clin-
icopathologic feature of PTMC that are predictive of
central LNM.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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factor in patients with conventional papillary thyroid
carcinoma (PTC), it is not prognostic in patients with
PTMC; rather, patients with PTMC have different clin-
ical features and prognostic factors according to age
[16]. This study analyzed the clinical factors predictive
of central LNM according to age in PTMC patients
without definite central LNM, with an emphasis on de-
termining whether tumor size is associated with central
LNM.
Methods
PTMC was defined as a subset of papillary thyroid can-
cer measuring ≤10 mm and has not grown outside the
thyroid (pT1a) by American Joint Committee on Cancer
(AJCC)/World Health Organization (WHO) 2009 tumor
node metastasis (TNM). Before this definition, the only
criterion of PTMC was the size regardless of having
extrathyroidal extension of tumor. So we analyzed all
PTC measuring ≤10 mm, and the subgroup of tumor
without extrathyroidal extension (true PTMC) was suba-
nalysed. Tumor size was confirmed by surgical path-
ology in all patients. Preoperative physical examination
and ultrasonography showed that all patients were clin-
ically lymph node negative.
The medical records of patients who underwent
thyroid surgery for malignancy from January 2005 to
December 2013 in our hospital were reviewed. Patients
with other malignancies and those with a history of
previous thyroid surgery were excluded. Of the 1,058Table 1 The clinical and histopathological characteristics of the
Characteristics All patients
Enrolled patients 428
Sex (M/F) 67/361 (15.7%/84.





Less than total 131
Tumor size (cm), mean ± SD (range) 0.66 ± 0.23 (0.1 to
Multifocality (%) 116 (27.1%)
Central lymph node metastasis (%) 96 (22.4%)
No. of metastasis
1 to 3 71
4 to 10 25
Thyroiditis (%) 53 (12.4%)
Extrathyroidal extension (%) 146 (34.1%)
M, male; F, female; SD, standard deviation; No., number.patients with PTC, 538 patients were diagnosed as hav-
ing a tumor of size 10 mm. Among them, 428 patients
underwent thyroidectomy with unilateral or bilateral
central lymph node dissection.
Patients were divided into two groups by age at diag-
nosis, <45 and ≥45 years, respectively. Tumor sizes in
patients with and without LNM were compared using
Student’s t-tests. Univariate and multivariate analyses
were performed to identify clinicopathologic factors as-
sociated with central LNMs. Odds ratio (OR) and 95%
confidence interval (CI) were calculated to determine
the relevance of all potential predictors of central LNM.
Cumulative central LNM risk was determined using the
Kaplan-Meier method and compared using the log-rank
test. All statistical analyses were performed using SPSS
(version 19.0 SPSS Inc., Chicago, IL, USA). Significance
was defined as P < 0.05. The study protocol including
the use of the database was approved by the Institutional
Review Board of Gyeongsang National University Hospital
and met the guidelines of the responsible governmental
agencies.Results
The clinical and histopathological characteristics are given
in Table 1. Of the 428 patients, they ranged in age from 15
to 80 years, with 264 patients being ≥45 years old. Central
LNMs were identified in 96 patients (22.4%), with 25
(5.8%) having four or more LNMs. By definition, 282 pa-
tients were classified as PTMC.patients with papillary thyroid cancer measuring ≤1 cm
Patients without extrathyroidal extension
282
3%) 44/238 (15.6%/84.4%)











Table 2 Analysis for risk factors of central lymph node metastasis of the patients with papillary thyroid cancer
measuring ≤1 cm
Univariate analysis Multivariate analysis
Odd ratio P value 95% CI Odd ratio P value 95% CI
Sex (male) 0.719 0.425 0.37 to 1.41
Age≥ 45 years 0.378 0.057 0.40 to 1.00
Size > 0.5 cm 2.084 0.006 1.23 to 3.52 1.967 0.015 1.14 to 3.39
Mutifocality 2.554 <0.001 1.58 to 4.13 2.269 0.001 1.39 to 3.70
Extrathyroidal extension 1.908 0.006 1.20 to 3.04 1.699 0.030 1.05 to 2.74
Thyroiditis 1.143 0.696 0.58 to 2.24
Preoperative TSH (continuous variable) 0.917 0.307 0.78 to 1.08
A multivariate analysis was set by using all of the predictors with p values under 0.05 in univariate analysis.
TSH, thyroid stimulating hormone; CI, confidence interval.
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measuring ≤1 cm
Univariate analysis showed that central LNM of patients
with PTC measuring ≤1 cm was significantly associated
with tumor size, multifocality, and extrathyroidal ex-
tension. The rate of central LNM was higher in pa-
tients <45 years than that in patients ≥45 years
(26.8% vs. 19.3%, P = 0.068) However, patient age was
not significantly associated with LNM using cutoffs of
40, 45, and 50 years. Multiple logistic regression analysis
showed that tumor size >0.5 cm was an independent
predictor of central LNMs in study patients (OR = 1.967
P = 0.015) (Table 2).
Tumor size as a predictor of central LMNs according to
age group
Mean tumor size was significantly larger in patients with
than without central LNM (0.74 ± 0.22 vs. 0.64 ± 0.23 cm,
P = 0.001). Among patients <45 years old at the time of
diagnosis, mean tumor size did not differ by LNM statusFigure 1 Cumulative risk of central lymph node metastasis according to
(b) PTMC patients.(P = 0.635). However, in patients aged ≥45 years at diag-
nosis, tumor size was significantly larger in patients
with than without LNM (0.71 vs. 0.61 cm, p = 0.018).
We therefore analyzed the cumulative risk of central
LNM in each age group, by comparing patients with
tumors <0.5 and ≥0.5 cm. Among patients <45 years
old, those with PTMCs <0.5 and ≥0.5 cm had similar
cumulative risks of central LNM. However, among pa-
tients ≥45 years old, those with larger tumors had a
greater cumulative risk of central LNM than those with
smaller tumors (Figure 1).
Logistic regression analysis was performed to determine
factors significantly associated with central LNM in the
two age groups. In patients ≥45 years old, large tumor size
(OR = 3.167, P = 0.006) and multifocality (OR = 2.098, P =
0.025) were significantly associated with central LNM. In
patients <45 years old, multifocality was the only signifi-
cant predictor of central LNM (OR = 2.829, P = 0.009);
tumor size was not associated with central LNM in this
group (P = 0.635) (Table 3).age at diagnosis. (a) All PTC patients with tumor measuring <1 cm.
Table 3 Risk factors of central lymph node metastasis according to age groups in all patients
Group I (age < 45 years) Group II (age ≥ 45 years)
Odd ratio P value 95% CI Odd ratio P value 95% CI
Size > 0.5 cm 1.206 0.635 0.56 to 2.62 3.167 0.006 1.40 to 7.16
Multifocality 2.829 0.009 1.30 to 6.18 2.098 0.025 1.10 to 4.02
Extrathyroidal extension 1.935 0.075 0.94 to 3.99 1.534 0.194 0.80 to 2.93
Kim et al. World Journal of Surgical Oncology  (2015) 13:88 Page 4 of 6Factors associated with central LNM of patients with
PTMC
The result was similar in patients with PTMC (without
extrathyroidal extension). The rate of central LNM was
higher in patients <45 years than that in patients ≥45 years
(22.2% vs. 16.1%). Tumor size was the only significant pre-
dictor of central LNM in PTMC patients ≥45 years old
(OR = 6.875, P = 0.002) (Table 4).
Discussion
Results from this study showed that the size of PTMCs
was an independent predictor of subclinical central
LNM only in patients ≥45 years old at the time of diag-
nosis. Although other studies assessed the clinicopatho-
logical factors associated with subclinical central LNM
in patients with PTMC, those results were inconsistent.
In particular, it was unclear whether tumor size and age
at diagnosis were predictors of subclinical central LNM.
Previous studies have suggested that tumor size is an
independent predictor of subclinical central LNM of
PTMC [17-23], but the size cutoffs differed across those
studies. Although a study reported that a threshold of
6 mm may be more appropriate than 5 mm [23], most
studies to date have used 5 mm as the size threshold
and have analyzed the aggressiveness of PTMCs. In the
study by Parkdaman et al. [19], there were no differences
in lymph node metastasis according to cutoff of size 5
vs. 4 mm. Also, in another study of multivariate analysis
[24], they found that a size cutoff of 5 mm was not an
independent predictor of subclinical central LNM. In
our study, the analysis of all patients showed that tumor
size, both as a continuous variable and using a cutoff ofTable 4 Risk factors of central lymph node metastasis accord
extension
Group I (age < 45 years)
Odd ratio P value 95% CI
Size > 0.5 cm 1.420 0.485 0.53 to
Multifocality 2.731 0.057 0.97 to
Sex (male) 0.282 0.553 0.32 to
Thyroiditis 0.497 0.380 0.10 to
TSH 0.900 0.582 0.62 to
TSH, thyroid stimulating hormone; CI, confidence interval.5 mm, was a significant predictor of central LNM. How-
ever, in the subgroup of PTMC patients <45 years at
diagnosis, tumor size was not associated with central
LNM.
Age is an important prognostic factor in patients with
PTCs > 1 cm; however, its prognostic value in PTMC
has been uncertain, with inconsistent results among
studies [17,20,23-25]. A cutoff age of 45 years is widely
used as a clinically prognostic marker [22]. In analyzing
the incidence of central LNM according to patient age,
we observed a trend to an inverse relationship. However,
a detailed analysis showed fluctuations according to age
groups (Figure 2). Hence, the difference in age distribu-
tion in each of the previous studies doubtlessly affected
the associations between age and central LNM.
This study found that multifocality was a significant
predictor of central LNM regardless of age group in pa-
tients with PTC measuring ≤1 cm. Similarly, a meta-
analysis of 1,789 patients with PTMC showed a signifi-
cant association between multifocality and LNM in
PTMC (OR, 1.9; 95% CI 1.6 to 2.4, P < 0.001) [25].
This study confirmed that factors predictive of central
LNM in patients with PTMC differed by age. It is im-
portant to determine whether central LNM is associated
with prognosis in PTMC patients. Although lateral neck
LNM has been considered prognostic in patients with
PTMC, the prognostic importance of central LNM is
unclear. Several studies found that central LNM was not
prognostic [6,10]. However, we previously reported that
the patients with PTMCs had different clinical features
and prognostic factors according to age [16]. Thus, re-
gardless of the relationship of central LNM and prognosis,ing to age groups in patients without extrathyroidal
Group II (age ≥ 45 years)
Odd ratio P value 95% CI
3.80 6.875 0.002 1.99 to 23.78
7.68 2.052 0.097 0.88 to 4.79
3.72 0.223 0.082 0.02 to 1.38
2.37 1.694 0.282 0.65 to 4.43
1.31 0.945 0.678 0.73 to 1.23
Figure 2 Central lymph node metastasis rate in patients aged <45
and ≥45 years.
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treatment and follow-up to patient age.
This study has several limitations. Due to its retro-
spective nature, there may have been a selection bias.
Moreover, our study population was a cohort of patients
cared for in a single center. The limited number of our
patients, despite the statistical adjustments for small
specimens, compels us to emphasize the need for further
studies, with larger series of patients, in order to test our
results. Also, we only focused the clinicopathologic
factors to predict central LNM irrespectively of the im-
aging features of PTMC such as ultrasound or computer
tomography.
Conclusions
The rate of central LNM in PTMC patients ≥45 years
old was significantly low in patients who had small
tumor measuring ≤0.5 cm. Therefore, these patients
might be safe without prophylactic central LN dissec-
tion. However, tumor size in PTMC patients <45 years
old was not a predictive factor of central LNM.
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